Efavirenz and Rifampicin in the South African Context: Is There a Need to Dose-Increase Efavirenz with Concurrent Rifampicin Therapy?

Abstract

Background

Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations

Methods

Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant tuberculosis (TB) were dosed with either increased (800 mg) or standard (600 mg) dose EFV during TB treatment. After TB therapy, all individuals took 600 mg EFV. Two mid-dosing interval EFV concentrations were determined from each individual: after 4 weeks of concomitant EFV and RFN therapy, and ≥4 weeks after TB therapy completion. Mid-dosing interval EFV concentrations were compared within individuals using the Wilcoxon signed– rank test.

Results

Paired samples were collected from 72 individuals. Overall, 45 (63%) were women and median weight was 59 kg (IQR 52–67). At antiretroviral therapy start, median CD4⁺ T-cell count was 114 cells/mm³ (IQR 37–165), median viral load was 5.5 log (IQR 5.1–5.9). A total of 38 (53%) individuals took 800 mg EFV during TB treatment and 34 (47%) took 600 mg. EFV concentrations in the 800 mg group were higher with RFN (2.9 mg/l [IQR 1.8–5.6]) than without (2.1 mg/l [IQR 1.4–3.0]; P=0.0003). There was no significant difference in EFV concentrations with RFN (2.4 mg/l [IQR 1.2–5.1]) or without (2.2 mg/l [IQR 1.4–3.7]) in the 600 mg group. There was no increase in EFV-linked adverse effects in either group. The proportion of virologically suppressed individuals at 48 weeks was similar in both groups.

Conclusions

EFV concentrations were significantly increased in the EFV 800 mg group on RFN. There was no significant decrease in EFV concentrations when on RFN in the 600 mg group. Dose escalation of EFV 600 mg to 800 mg is not required during concomitant TB therapy in South Africa.

References

National Department of Health, South Africa. National antiretroviral treatment guidelines. (Updated April 2004. Accessed 27 June 2010.) Available from http://hst.org.za/uploads/files/sa_ART_Guidelines1.pdf.

National Department of Health, South Africa. Clinical guidelines for the management of HIV & AIDS in adults and adolescents. (Updated April 2010. Accessed 6 June 2010.) Available from http://www.doh.gov.za/docs/.

Ståhle

, Moberg

, Svensson

J.O.

, Sönnerborg

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004; 26: 267–270.

Marzolini

, Telenti

, Decosterd

L.A.

, Greub

, Biollaz

, Buclin

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71–75.

Gutiérrez

, Navarro

, Padilla

Prediction of neuro-psychiatric adverse events associated with long term efavirenz therapy, using plasma level monitoring. Clin Infect Dis 2005; 41: 1648–1653.

Kappelhoff

B.S.

, van Leth

, Robinson

P.A.

Are adverse events of nevirapine and efavirenz related to plasma levels?

Antivir Ther 2005; 10: 489–498.

Núñez

, González de Requena

, Gallego

, Jiménez-Nácher

, González-Lahoz

, Soriano

Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001; 28: 399–400.

Badri

, Wilson

, Wood

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059–2064.

National Department of Health, South Africa. South African tuberculosis control programme practical guidelines. (Updated 11 July 2000. Accessed 27 June 2010.) Available from http://www.capegateway.gov.za/Text/2003/tb_guidelines2000.pdf.

10.

Lawn

S.D.

, Wilkinson

R.J.

, Lipman

M.C.

, Wood

Immune reconstitution and ‘unmasking’ of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680–685.

11.

Benedek

, Joshi

, Fiske

W.O.

Pharmacokinetic interaction between rifampicin and efavirenz in healthy volunteers. 12th World AIDS Conference. 28 June–3 July 1998, Geneva, Switzerland. Abstract 42280.

12.

López-Cortés

L.F.

, Ruiz-Valderas

, Viciana

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681–690.

13.

Sustiva (efavirenz) Package insert 2008. Prescribing Information. Bristol–Meyers Squibb Pharma Company, Princeton, NJ, USA. (Updated November 2010. Accessed 27 June 2010.) Available from http://packageinserts.bms.com/pi/pi_sustiva.pdf.

14.

Lewthwaite

, Gibbons

, Vilar

, Khoo

Efavirenz, rifampicin and rifabutin – a case for therapeutic drug monitoring. 2nd IAS Conference on HIV Pathogenesis and Treatment. 13–16 July 2003, Paris, France. Abstract 851.

15.

Brennan-Benson

, Lyus

, Harrison

, Pakianathan

, Macallan

Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19: 1541–1543.

16.

Ramachandran

, Hemanth Kumar

A.K.

, Rajasekaran

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009; 53: 863–868.

17.

Boulle

, Van Cutsem

, Cohen

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530–539.

18.

Pedral-Sampaio

D.B.

, Alves

C.R.

, Netto

E.M.

, Brites

, Oliveira

A.S.

, Badaro

Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis 2004; 8: 211–216.

19.

Cohen

, Grant

, Dandara

Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14: 687–695.

20.

Manosuthi

, Kiertiburanakul

, Sungkanuparph

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20: 131–132.

21.

Sanne

, Orrell

, Fox

M.P.

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010; 376: 33–40.

22.

Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004. (Updated August 2009. Accessed 07 April 2011.) Available from http://rcc.tech-res.com/safetyandpharmacovigilance/.

23.

Ren

, Nuttall

J.J.

, Egbers

High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007; 45: 133–136.

24.

Chi

, Jayewardene

A.L.

, Stone

J.A.

, Motoya

, Aweeka

F.T.

Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. J Pharm Biomed Anal 2002; 30: 675–684.

25.

Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. (Updated 18 May 2008. Accessed 4 January 2010.) Available from http://www.cdc.gov/tb/publications/guidelines/HIV_AIDS.htm.

26.

Robertson

S.M.

, Oenzak

S.R.

, Pau

Drug interactions in the management of HIV infection: an update. Expert Opin Pharmacother 2007; 8: 2947–2963.

27.

Uttayamakul

, Likanonsakul

, Manosuthi

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010; 7: 8.

28.

DiGiacinto

J.L.

, Chan-Tack

K.M.

, Robertson

S.M.

, Reynolds

K.S.

, Struble

K.A.

Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. J Clin Pharmacol 2008; 48: 518–523.